Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

NASDAQ:RCEL - US05380C1027 - Common Stock

4.19 USD
-0.05 (-1.18%)
Last: 9/9/2025, 8:04:34 PM
4.19 USD
0 (0%)
After Hours: 9/9/2025, 8:04:34 PM
Fundamental Rating

3

Overall RCEL gets a fundamental rating of 3 out of 10. We evaluated RCEL against 541 industry peers in the Biotechnology industry. Both the profitability and financial health of RCEL have multiple concerns. RCEL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RCEL has reported negative net income.
In the past year RCEL has reported a negative cash flow from operations.
RCEL had negative earnings in each of the past 5 years.
RCEL had a negative operating cash flow in each of the past 5 years.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RCEL has a Return On Assets of -88.71%. This is in the lower half of the industry: RCEL underperforms 72.27% of its industry peers.
Industry RankSector Rank
ROA -88.71%
ROE N/A
ROIC N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

RCEL's Operating Margin of 245.35% is amongst the best of the industry. RCEL outperforms 100.00% of its industry peers.
RCEL has a better Gross Margin (392.18%) than 99.82% of its industry peers.
RCEL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 245.35%
PM (TTM) N/A
GM 392.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCEL remains at a similar level compared to 1 year ago.
Compared to 1 year ago, RCEL has a worse debt to assets ratio.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RCEL has an Altman-Z score of 2.89. This is not the best score and indicates that RCEL is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.89, RCEL is doing good in the industry, outperforming 70.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.89
ROIC/WACCN/A
WACC10.96%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.58 indicates that RCEL may have some problems paying its short term obligations.
RCEL has a Current ratio of 0.58. This is amonst the worse of the industry: RCEL underperforms 92.79% of its industry peers.
RCEL has a Quick Ratio of 0.58. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of RCEL (0.46) is worse than 92.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.46
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

RCEL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
Looking at the last year, RCEL shows a very strong growth in Revenue. The Revenue has grown by 38.31%.
The Revenue has been growing by 30.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)38.31%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.21%

3.2 Future

RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.26% yearly.
RCEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.07% yearly.
EPS Next Y65.99%
EPS Next 2Y36.69%
EPS Next 3Y26.66%
EPS Next 5Y34.26%
Revenue Next Year21.43%
Revenue Next 2Y28.15%
Revenue Next 3Y35.13%
Revenue Next 5Y39.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RCEL indicates a rather cheap valuation: RCEL is cheaper than 99.45% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.73
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCEL's earnings are expected to grow with 26.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.69%
EPS Next 3Y26.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (9/9/2025, 8:04:34 PM)

After market: 4.19 0 (0%)

4.19

-0.05 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners26.63%
Inst Owner Change8.72%
Ins Owners0.76%
Ins Owner Change3.01%
Market Cap111.54M
Analysts75.38
Price Target9.79 (133.65%)
Short Float %20.38%
Short Ratio14.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.59%
Min EPS beat(2)-50.22%
Max EPS beat(2)-34.96%
EPS beat(4)1
Avg EPS beat(4)-31.02%
Min EPS beat(4)-50.22%
Max EPS beat(4)0.41%
EPS beat(8)3
Avg EPS beat(8)-17.16%
EPS beat(12)5
Avg EPS beat(12)-11.92%
EPS beat(16)9
Avg EPS beat(16)-0.84%
Revenue beat(2)0
Avg Revenue beat(2)-17.14%
Min Revenue beat(2)-20.13%
Max Revenue beat(2)-14.15%
Revenue beat(4)0
Avg Revenue beat(4)-12.47%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-1.35%
Revenue beat(8)2
Avg Revenue beat(8)-6.77%
Revenue beat(12)6
Avg Revenue beat(12)-1.55%
Revenue beat(16)9
Avg Revenue beat(16)0.25%
PT rev (1m)-40.47%
PT rev (3m)-43.11%
EPS NQ rev (1m)-120.92%
EPS NQ rev (3m)-92.92%
EPS NY rev (1m)-16.55%
EPS NY rev (3m)-19.52%
Revenue NQ rev (1m)-23.01%
Revenue NQ rev (3m)-25.68%
Revenue NY rev (1m)-18.41%
Revenue NY rev (3m)-18.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.73
EPS(TTM)-1.97
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS2.81
BVpS-0.48
TBVpS-0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -88.71%
ROE N/A
ROCE -4112.02%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 245.35%
PM (TTM) N/A
GM 392.18%
FCFM N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score4
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 341.35%
Cap/Sales 8.17%
Interest Coverage 31.61
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.46
Altman-Z 2.89
F-Score4
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next Y65.99%
EPS Next 2Y36.69%
EPS Next 3Y26.66%
EPS Next 5Y34.26%
Revenue 1Y (TTM)38.31%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.21%
Revenue Next Year21.43%
Revenue Next 2Y28.15%
Revenue Next 3Y35.13%
Revenue Next 5Y39.07%
EBIT growth 1Y440.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.45%
EBIT Next 3Y27.19%
EBIT Next 5Y22.45%
FCF growth 1Y-66.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.98%
OCF growth 3YN/A
OCF growth 5YN/A